Don Berry

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors

Susan M. Chang, M. Mehta, P. Wen, 2021, Journal for ImmunoTherapy of Cancer.

Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD‐5)

J. Chien, M. Heathman, S. Berry, 2014, Diabetes, obesity & metabolism.

Adaptive Dose-Response Studies

Paul Gallo, Brenda Gaydos, Michael Krams, 2006 .

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease

D. Berry, Scott Berry, C. Swanson, 2022, Alzheimer's research & therapy.

Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial

R. Lewis, W. Barsan, K. Johnston, 2022, JAMA network open.

An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics

J. Chien, S. Berry, Z. Skrivanek, 2012, Journal of diabetes science and technology.

Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations

Brenda Gaydos, Zachary Skrivanek, Mary Jane Geiger, 2012, Journal of diabetes science and technology.